Pharma Workforce Barbell Shift

Pharma’s Workforce Is Splitting in Two: The Growing Divide Between AI-Driven Specialists and Declining Generalist Roles

The pharmaceutical and biotechnology industries have always been cyclical – shaped by patent cliffs, regulatory shifts, and waves of scientific innovation. Yet what is unfolding now is different in both pace and structure. We are not simply witnessing another hiring correction. We are seeing a fundamental reconfiguration of the workforce itself.

At a macro level, the industry’s talent model is beginning to resemble a barbell: weight concentrated at two ends, with a thinning middle. On one side sit highly specialised, high-impact experts, increasingly augmented by artificial intelligence and advanced data capabilities. On the other, a narrower layer of executional and support roles. Between them, the traditional mid-level generalist – the long-standing backbone of pharma organisations – is being steadily eroded.

This is not an isolated workforce trend. It is a reflection of deeper economic and technological forces reshaping how value is created across life sciences.

From scale to precision

For decades, scale was a defining advantage in pharma. Large, layered teams supported complex global trials, regulatory processes, and commercial operations. Redundancy, in many cases, was a feature rather than a flaw – ensuring resilience in a high-risk environment.

Today, that logic is shifting.

R&D productivity remains under intense scrutiny, while the cost of bringing a drug to market continues to rise. At the same time, advances in computational biology, machine learning, and automation are enabling organisations to do more with fewer people – but only if those people possess the right capabilities.

According to McKinsey & Company, the application of AI across pharmaceutical R&D could unlock productivity gains of up to 20–30% in early discovery. This is not merely an efficiency gain; it is a redefinition of how work gets done. Tasks that once required teams can now be accelerated – or partially replaced – by algorithms, platforms, and integrated data systems.

The implication is clear: value is no longer created by scale alone, but by precision – deploying highly capable individuals at the points of greatest impact.

The ascent of the hybrid expert

At one end of the barbell, demand is intensifying for individuals who operate at the intersection of disciplines. These are scientists who code, clinicians who analyse real-world datasets, and regulatory leaders who understand the implications of AI-generated evidence.

What distinguishes these individuals is not just depth of expertise, but their ability to navigate complexity – connecting biology, data, and decision-making in ways that accelerate outcomes.

This shift is visible across the industry. Whether in oncology, rare diseases, or advanced therapies, organisations are prioritising roles that directly influence probability of technical and regulatory success. The premium placed on such talent is rising accordingly, both in compensation and in strategic importance.

In this context, the notion of the “10x contributor” is no longer confined to the technology sector. It is becoming increasingly relevant in life sciences.

The hollowing of the middle

At the same time, the centre of the workforce is under pressure.

Mid-level generalist roles – often characterised by broad but not deep expertise – are being re-evaluated. Many of the tasks associated with these roles are either being automated, standardised, or redistributed. Digital tools are streamlining documentation, analytics platforms are reducing manual data handling, and global operating models are consolidating functions that were once dispersed.

Research from the OECD highlights a broader economic pattern: employment is increasingly polarising, with growth concentrated in high-skill and low-skill roles, and relative decline in the middle. Pharma is now experiencing this dynamic in a highly specialised form.

It is important to emphasise that this is not about redundancy in a simplistic sense. The work itself is not disappearing; it is being reshaped. Fewer individuals are required to perform it, and those who remain are expected to operate with greater technical fluency and adaptability.

Why this shift is happening now

Several forces are converging to accelerate the barbell effect:

• AI integration: Not as a replacement for scientists, but as a force multiplier that reduces the need for layered teams
• Capital discipline: Investors are demanding clearer returns, forcing companies to prioritise roles tied directly to value creation
• Clinical risk: With high failure rates, organisations are concentrating resources on areas with the highest probability of success
• Operational efficiency: Large pharma continues to streamline global footprints, reducing duplication and generalist functions

The result is a workforce model where impact per employee matters more than headcount scale.

Capital discipline and strategic focus

Overlaying these technological shifts is a more disciplined capital environment. The exuberance that characterised parts of the biotech sector in the early 2020s has given way to a sharper focus on returns, pipeline prioritisation, and operational efficiency.

This has tangible implications for workforce design. Hiring decisions are increasingly tied to clear value creation metrics. Roles that cannot be directly linked to advancing the pipeline or enabling critical capabilities are subject to greater scrutiny.

In practical terms, this reinforces the barbell effect. Investment flows toward high-impact expertise, while broader, less differentiated roles face compression.

A more complex talent equation

The result is a more complex and, in some respects, more fragile talent ecosystem.

On one hand, there is a surplus of experienced professionals whose skill sets were well aligned to previous operating models. On the other, there is a persistent shortage of individuals who can meet the emerging demands of a data-driven, AI-enabled industry.

This imbalance creates risk. Critical roles remain unfilled, innovation timelines are extended, and organisational agility is constrained. At the same time, the social and cultural implications of workforce polarisation cannot be ignored, particularly in an industry that has long relied on collaborative, multidisciplinary teams.

Rethinking talent strategy for the next decade

If the barbell effect is indeed the new structural reality – and there is increasing evidence that it is – then talent strategy must evolve accordingly.

First, organisations will need to become far more deliberate in how roles are defined. The distinction between specialist and generalist is no longer sufficient; the focus must shift to capability clusters that align with future value creation.

Second, investment in upskilling and reskilling will be critical. Bridging the gap between traditional scientific expertise and emerging technological capabilities is not a short-term exercise, but it is essential for maintaining organisational coherence.

Third, access to talent will need to be broadened. The most sought-after individuals are often not actively seeking new roles and may sit outside traditional networks or geographies. Identifying and engaging this talent requires a more sophisticated, insight-led approach.

Finally, partnerships across the talent ecosystem will play an increasingly important role. As roles become more specialised and harder to fill, organisations will need to draw on external expertise, market intelligence, and deep sector networks to complement their internal capabilities.

The pharmaceutical workforce is not shrinking in a linear sense – it is being reshaped. Those who recognise the structural nature of this shift, and adapt their talent strategies with equal precision, will be best positioned to lead in the next era of life sciences innovation.

By Carl Marotta, CEO, Skills Alliance